ADROIQ Trademark

Trademark Overview

On Tuesday, July 6, 2021, a trademark application was filed for ADROIQ with the United States Patent and Trademark Office. The USPTO has given the ADROIQ trademark a serial number of 90813452. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, June 27, 2024. This trademark is owned by EXTROVIS AG. The ADROIQ trademark is filed in the Pharmaceutical Products category with the following description:

Anti-epileptic pharmaceutical preparations; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of kidney diseases
adroiq

General Information

Serial Number90813452
Word MarkADROIQ
Filing DateTuesday, July 6, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, June 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 3, 2022

Trademark Statements

Goods and ServicesAnti-epileptic pharmaceutical preparations; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of kidney diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEXTROVIS AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBaar 6340
CH
Party NameEXTROVIS AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBaar 6340
CH

Trademark Events

Event DateEvent Description
Saturday, July 10, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 9, 2021NEW APPLICATION ENTERED
Saturday, July 10, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, July 10, 2021TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Saturday, July 10, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 28, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 24, 2022ASSIGNED TO EXAMINER
Monday, March 28, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, March 28, 2022EXAMINERS AMENDMENT E-MAILED
Monday, March 28, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, March 28, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, April 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 3, 2022PUBLISHED FOR OPPOSITION
Tuesday, May 3, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 28, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 26, 2022SOU TEAS EXTENSION RECEIVED
Monday, December 26, 2022SOU EXTENSION 1 FILED
Monday, December 26, 2022SOU EXTENSION 1 GRANTED
Wednesday, December 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 26, 2023SOU TEAS EXTENSION RECEIVED
Monday, June 26, 2023SOU EXTENSION 2 FILED
Monday, June 26, 2023SOU EXTENSION 2 GRANTED
Wednesday, June 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 29, 2024ABANDONMENT - NO USE STATEMENT FILED
Thursday, December 28, 2023SOU EXTENSION 3 FILED
Wednesday, February 14, 2024TEAS PETITION TO REVIVE RECEIVED
Monday, January 29, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, February 14, 2024PETITION TO REVIVE-GRANTED
Wednesday, February 14, 2024TEAS PETITION TO REVIVE RECEIVED
Wednesday, February 14, 2024NOTICE OF REVIVAL - E-MAILED
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 10, 2024SOU EXTENSION 3 GRANTED
Thursday, June 27, 2024SOU TEAS EXTENSION RECEIVED
Thursday, June 27, 2024SOU EXTENSION 4 GRANTED
Thursday, June 27, 2024SOU EXTENSION 4 FILED
Thursday, June 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

adroiq pharmaceutical preparations diseases treatment disorders substances psychiatric system ophthalmic dysfunction